Bob Duggan, Summit CEO (via Summit Investments)
December 21, 2021 11:25 AM ESTUpdated 12:16 PM
R&D

Bil­lion­aire Bob Dug­gan's new an­tibi­ot­ic play fails a Phase III tri­al, and in­vestors aren't hap­py

Nicole DeFeudis

Editor

Bob Dug­gan — the bil­lion­aire in­vestor fa­mous for turn­ing Phar­ma­cyclics from a pen­ny stock to a $20 bil­lion com­pa­ny — placed a hand­some bet on the com­pa­ny …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ex­clu­sive: In­flu­en­tial De­mo­c­rat will op­pose Biose­cure Act ahead of House vote

Astel­las CEO talks fu­ture be­yond Xtan­di as Japan­ese drug­mak­er puts roots in Boston

Bridge­Bio sticks to script for AT­TR-CM as Al­ny­lam cleans up ‘ty­po’ sna­fu

Roche's Spark los­es CEO to RNA up­start; Ex-El­e­va­tion On­col­o­gy chief takes over at Af­fimed

Lil­ly inks obe­si­ty deal with seed-stage RNA start­up as its ge­net­ic med­i­cines ef­fort en­ters the spot­light

sponsored

How to se­cure full en­roll­ment and a 30x ROI: A con­ver­sa­tion with the CEO of the bou­tique en­roll­ment agency do­ing just ...

A service from the Financial Times